Farcast Biosciences announced ISO 9001 certification for its hTMD platform. TÜV NORD issued certification covering TruTumor culturing, pathology, assaying, and data generation technologies.
Farcast Biosciences announced a name change to Farcast Biodynamics and described a system combining tumor microenvironment perturbation signals, blood-draw signals, and biosignature computation.
Farcast published data in Nature Communications demonstrating pre-detection of patient response cohorts for nivolumab. Its technology uses biosignatures from live human tumor data and AI models to predict clinical response.
Farcast is extending its tumor microenvironment platform with TruPower, which incorporates peripheral markers from patient blood samples to elucidate cancer response without tissue biopsies or surgery samples.
The company pioneered human tumor histoculture science and has invested in understanding how to recreate near-native human tumor immune microenvironments (TiME) ex vivo.
The Privacy Policy describes how information is collected, used, and disclosed when users use the Service, and outlines privacy rights and legal protections.
